Hyperuricemia With or Without GoutPhase 3NCT03372200
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
A Phase 3 study testing FYU-981 and Febuxostat in people with Hyperuricemia With or Without Gout, run by Mochida Pharmaceutical Company, Ltd. at 1 site in Japan.
Trial summary
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Hyperuricemia With or Without Gout
- What is being tested?
- FYU-981 and Febuxostat
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 203 participants
- Where
- 1 siteJapan
- Study dates
- 9 Jan 2018to 5 Jul 2018
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Serum urate level:
- >= 7.0mg/dL in patients with gouty nodule or with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
- Disease type in the classification of hyperuricemia: Uric acid-underexcretion type or mixed type
- Outpatients
Who cannot join
- Gouty arthritis within 14 days before randomized allocation
- Secondary hyperuricemia
- HbA1c: >= 8.4%
- Clinically significant cardiac, hepatic, renal, hematologic or endocrine disease
- Kidney calculi or clinically significant urinary calculi
- AST: >= 100 IU/L or ALT: >= 100 IU/L
- eGFR: < 30 mL/min/1.73m^2
- Systolic blood pressure: >= 180 mmHg or diastolic blood pressure: >= 110 mmHg
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.
- Conditions
- Hyperuricemia With or Without Gout
- Being tested
- FYU-981, Febuxostat
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FYU-981Drug
Oral daily dosing for 14 weeks
FebuxostatDrug
Oral daily dosing for 14 weeks
| Study group | Role | What they receive |
|---|---|---|
| FYU-981 | Experimental | Not described Receives: Drug: FYU-981 |
| Febuxostat | Active comparator | Not described Receives: Drug: Febuxostat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent reduction from baseline in serum urate level at the final visit
Percent reduction from baseline in serum urate level at the final visit
Measured: 14 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2017
- Study start9 Jan 2018
- Primary completion4 Jun 2018
- Study completion5 Jul 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hyperuricemia With or Without GoutStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 203 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Fuji Yakuhin Co., Ltd.
- Responsible party
- Sponsor
- Investigators
- Kazuki Furuno, Study director, Clinical Research Department
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03372200
- Sponsor's protocol ID
- FYU-981-014
- Status last verified
- Sep 2018
- First submitted
- 10 Dec 2017
- Last updated
- 24 Sep 2018
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)
- ClinicalTrials.gov ID
- NCT03372200
- Acronym / sponsor ID
- FYU-981-014
- Conditions
- Hyperuricemia With or Without Gout
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 203 participants (actual)
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Fuji Yakuhin Co., Ltd.
- Study start
- 9 Jan 2018 (actual)
- Primary completion
- 4 Jun 2018 (actual)
- Study completion
- 5 Jul 2018 (actual)
- First posted
- 13 Dec 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| FYU-981 | Experimental | Drug: FYU-981 |
| Febuxostat | Active comparator | Drug: Febuxostat |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Serum urate level:
- Disease type in the classification of hyperuricemia: Uric acid-underexcretion type or mixed type
- Outpatients
Key exclusion criteria (8 listed)
- Gouty arthritis within 14 days before randomized allocation
- Secondary hyperuricemia
- HbA1c: >= 8.4%
- Clinically significant cardiac, hepatic, renal, hematologic or endocrine disease
- Kidney calculi or clinically significant urinary calculi
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FYU-981Oral daily dosing for 14 weeks | Drug | FYU-981 |
| FebuxostatOral daily dosing for 14 weeks | Drug | Febuxostat |
Primary outcome
Percent reduction from baseline in serum urate level at the final visit
Time frame: 14 weeks
Percent reduction from baseline in serum urate level at the final visit
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2018.
Related trials for Hyperuricemia With or Without Gout
Active, not recruitingPhase 1
Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects
Hyperuricemia With or Without Gout
Recruiting
Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia
Hyperuricemia With or Without Gout
Enrolling by invitationPhase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects
Hyperuricemia With or Without Gout
Recruiting
The Effects of a Probiotic Food Supplement in Hyperuricaemia
Hyperuricemia With or Without Gout
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kazuki Furuno study director
Clinical Research Department
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing FYU-981 and Febuxostat in people with Hyperuricemia With or Without Gout, run by Mochida Pharmaceutical Company, Ltd. at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent reduction from baseline in serum urate level at the final visit (time frame: 14 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2018.